SCN4A and rhabdomyolysis: In particular, the upregulation of SCN4A, a voltage-gated sodium channel, in simvastatin-treated cells may strengthen the inward-facing sodium current and exacerbate decreased serum potassium levels, thus increasing hypokalemic periodic muscle paralysis and rhabdomyolysis risk [72,73].